Get notified of page updates
Research & Clinical Trials > Search Results

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up-to-date on the latest hereditary cancer research.

How to Use Our Search and Enroll Tool

Printer Friendly Page

Featured Studies Results

Study Type: Treatment | Keyword: BRCA1

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT04674306

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence

Study of the Drug Sovilnesib in People with Ovarian Cancer

Study of the Drug Sovilnesib in People with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT06084416

Treatment
Treatment study for people with platinum-resistant ovarian cancer

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Clinicaltrials.gov identifier:
NCT05806515

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Clinicaltrials.gov identifier:
NCT05417594

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05252390

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Clinicaltrials.gov identifier:
NCT04038502

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Treating Early-Stage Breast Cancer  with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with  a BRCA or PALB2 Mutation

Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04584255

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Clinicaltrials.gov identifier:
NCT04644068

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Clinicaltrials.gov identifier:
NCT04548752

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Clinicaltrials.gov identifier:
NCT04666740

Treatment
Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment
This is a study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy

If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov


Sponsored By: